Last reviewed 2026-04-20 · How we verify

Staticum (GLISENTIDE)

Phase 2 active Small molecule

Staticum (generic name: GLISENTIDE) is a glisentide drug. It is currently in Phase 2 development.

Glisentide works by binding to a specific target, but the exact nature of this interaction is not well understood.

Staticum (Glisentide) is a small molecule drug in the glisentide class, but its target and exact mechanism of action are unknown. It is not clear if it has been approved by the FDA or if it is patented or off-patent. The approved indications for Staticum are also unknown. As a result, there is limited information available about its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand this medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GLISENTIDE
Drug class	glisentide
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and glisentide has a key that fits into one of those locks. When the key fits, it can turn the lock and change how the cell works. This can help to treat certain health conditions, but the details of how it works are still being studied.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Staticum CI brief — competitive landscape report
Staticum updates RSS · CI watch RSS

Frequently asked questions about Staticum

What is Staticum?

Staticum (GLISENTIDE) is a glisentide drug.

How does Staticum work?

Glisentide works by binding to a specific target, but the exact nature of this interaction is not well understood.

What is the generic name of Staticum?

GLISENTIDE is the generic (nonproprietary) name of Staticum.

What drug class is Staticum in?

Staticum belongs to the glisentide class. See all glisentide drugs at /class/glisentide.

What development phase is Staticum in?

Staticum is in Phase 2.

Drug class: All glisentide drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing